Post

Mediwound optimistic about wound therapy EscharEx after Phase II VLU trial

Israel-based MediWound has announced positive results from a head-to-head comparison of its wound treatment EscharEx versus standard of care (SoC) …

EMA CHMP recommends refusal of marketing authorisation for Nezglyal

The European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the refusal of the marketing authorisation …

NorthSea Therapeutics commences Phase IIa trial for IFALD therapy

NorthSea Therapeutics has kicked off its Phase IIa trial in intestinal failure-associated liver disease (IFALD) after the first patient was …

Pelvital’s Flyte device proves effective in published urinary continence study

Women’s health technology company Pelvital has published a study (NCT02954042) demonstrating the efficacy of its Flyte device to treat women …

ARC lays out clinical plan for surgical adhesion prevention liquid

Canada-based ARC Medical plans to evaluate its fluid medical devices, JOCOAT and IPCOAT, for the prevention or reduction of adhesions …